News | November 14, 2011

FDA’s Relabeling of Echo Contrast Agent Improves Patient Access

November 14, 2011 – The American Society of Echocardiography (ASE) reported that the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) has recognized the value of contrast agents in echocardiography and made very positive revisions to the U.S. label for Definity, an ultrasound contrast agent produced by Lantheus Medical Imaging.

“The end of the monitoring requirements will markedly simplify the process from both the patient and laboratory perspective.  The withdrawal of monitoring and new safety data on pulmonary hypertension offers further comfort to those who were on the fence about contrast,” said Jonathan Lindner, M.D., FASE, professor of medicine and associate chief for education in the Cardiovascular Division at Oregon Health and Science University in Portland, Ore.

Contrast-enhanced ultrasound (CEUS) involves the injection of an intravenous contrast medium before performing traditional medical sonography. ASE has long supported the use of ultrasound contrast agents for cardiovascular imaging in clinical practice because they assist physicians in maximizing the accuracy of information obtained from echocardiograms, particularly in difficult-to-image patients, thus optimizing patient care. Contrast plays a role in patient safety by reducing unnecessary exposure to ionizing radiation, and is cost effective, as it reduces the need for more invasive procedures downstream and reduces the number of repeat tests. With the support of ASE representatives on their board, the Intersocietal Commission for the Accreditation of Echocardiography Laboratories (ICAEL) recognized the important role of contrast agents in improving the accuracy of echocardiograms by including it in their revised standards for the accreditation of U.S. echocardiography laboratories in December 2010. ASE and ICAEL are collaborating on a webcast educational session in February 2012 to explain these new requirements to ASE members.

At an FDA meeting about the safety of contrast agents in May 2011, Sanjiv Kaul, M.D., FASE, FACC, then-president of the ASE, was a guest speaker for the FDA and provided a presentation on the current cardiology applications of contrast echocardiography, citing multiple cases in which the administration of contrast led to diagnoses that would not otherwise have been reached. James D. Thomas, M.D., FASE, FACC, then president-elect of the Society, represented ASE and documented the clinical utility of ultrasound contrast agents for a number of indications beyond those approved by the FDA at the time, including stress echocardiography (for left ventricular opacification), vascular imaging and myocardial perfusion imaging. He noted that ASE believes that these agents have broad applications beyond those currently approved, and encourages manufacturers to perform clinical trials to seek FDA approval for additional applications.

ASE has also fought hard for appropriate reimbursement for contrast administration. In the recently published Medicare Physician Fee Schedule, the Center for Medicaid and Medicare Services rejected ASE’s request for the establishment of additional contrast-enhanced echo Ambulatory Payment Classifications (APCs), but increased the APC rate for contrast-enhanced echo by almost $60. Under the final rates, the APC rate for contrast enhanced transthoracic echo (with spectral and color Doppler) is $164 more than unenhanced procedures, but the rate for contrast-enhanced stress echo is $23.68 less than for unenhanced stress echo.

The changes to the Definity label reflect the second FDA revision of warnings about contrast agents since boxed warnings were issued in 2007. More information about the relabeling is available on the Lantheus Website.  ASE commends Lantheus for their efforts in helping to clarify the safety and value of contrast as a diagnostic tool, and supports GE Healthcare’s efforts to seek similar label modifications for Optison, a contrast agent marketed by GE Healthcare. It is ASE’s understanding that GE will be submitting a label modification request later this year.

For more information: www.asecho.org

 

Related Content

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media| September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
Siemens Healthineers Receives FDA Clearance for TrueFusion Structural Heart Disease Feature
Technology | Cardiovascular Ultrasound| September 06, 2017
The U.S. Food and Drug Administration (FDA) has cleared TrueFusion, a new cardiovascular application from Siemens...
GE’s blood speckle imaging (BSI) software shows the flow of blood cells’ trajectories. It is a form of blood vector flow imaging.

GE’s blood speckle imaging (BSI) software offers the ability to view a graphical representation of the blood cells’ trajectories.

News | Cardiovascular Ultrasound| September 01, 2017
Cardiologists are constantly on the lookout for new methods to examine the heart using new imaging technology advance
Sponsored Content | Videos | Cardiovascular Ultrasound| August 30, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Sponsored Content | Videos | Cardiovascular Ultrasound| August 30, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Sponsored Content | Videos | Cardiovascular Ultrasound| August 30, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Sponsored Content | Videos | Cardiovascular Ultrasound| August 30, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media| August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Sponsored Content | Videos | Cardiovascular Ultrasound| August 28, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Overlay Init